<DOC>
	<DOC>NCT01361529</DOC>
	<brief_summary>The purpose of this study is to determine the tolerance and maximum tolerated dose (MTD) for FLP Injection with multiple dose in tumor patients.</brief_summary>
	<brief_title>Safety Study of FLP Injection to Treat Tumor Patients</brief_title>
	<detailed_description>To determine the tolerance and MTD for FLP Injection with multiple dose in tumor patients. To test clinical pharmacokinetics (PK) and PK parameter</detailed_description>
	<criteria>aged from 18 to 70 years old, male or female; histologically or cytologically proven advanced malignant solid tumors; cancer patients after conventional treatment failure and lack of effective treatment, or patients refusing effective treatment of existing practices; patients receiving the last treatment (chemotherapy, radiotherapy, biological therapy, targeted therapy, or other study drugs) for at least 4 weeks; expected survival time&gt;3 months; ECOG score 01 viral activity in patients allergic to drugs or excipients; hypersensitivity to paclitaxel injection patients; HIV antibody positive, or suffering from other acquired and congenital immune deficiency disease, or history of organ transplantation; neutrophil count &lt;1.5 × 109 / L, platelets &lt;100 × 109 / L, or hemoglobin &lt;90g / L; normal serum creatinine higher than 1.5 times the upper limit of reference range or the muscle of liver clearance &lt;60ml/min; no case of liver ALT or AST&gt; 2.5 times the upper limit of normal, or liver metastases than normal under the ALT or AST 5 times upper limit of reference range; fever or body temperature above 38 ℃ can be clinically significant impact on clinical trials of active infection; medications failed to control hypertension (systolic pressure is over 160 mmHg or diastolic pressure over 100mmHg); significant cardiovascular abnormalities (such as myocardial infarction, superior vena cava syndrome), or clinically significant arrhythmias (such as long QT syndrome, Corrected QTc not be measured or ≧ 480 ms); calcium, potassium, magnesium ions below the lower limit of normal; &gt; Ilevel peripheral neuropathy Prior to the toxicity of anticancer therapy has not been restored or not from the surgery before full recovery; bone metastases for the primary lesion of palliative radiotherapy; any clinical problems can not control (such as the serious mental, neurological, cardiovascular, respiratory and other diseases); a tumor metastasis, or a variety of mental disorders center; no history of asthma; pregnancy or breastfeeding women</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>May 2011</verification_date>
	<keyword>dose escalation</keyword>
</DOC>